In transit melanoma and imiquimod: A case of disease progression
- 1 July 2020
- journal article
- letter
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (4), e13512
- https://doi.org/10.1111/dth.13512
Abstract
Click on the article title to read more.This publication has 11 references indexed in Scilit:
- Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanomaExpert Review of Clinical Pharmacology, 2019
- Imiquimod cream in pediatric patients: Recommendations, adverse events, and controversiesDermatologic Therapy, 2019
- Cutaneous squamous cell carcinoma progression during imiquimod treatmentJournal of the American Academy of Dermatology, 2018
- The Dual Role of Cellular Senescence in Developing Tumors and Their Response to Cancer TherapyFrontiers in Oncology, 2017
- Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimodMelanoma Research, 2016
- Metastatic Melanoma – A Review of Current and Future Treatment OptionsActa Dermato-Venereologica, 2015
- Metastatic Volume: An Old Oncologic Concept and a New Prognostic Factor for Stage IV Melanoma PatientsDermatology, 2013
- Late Recurrence in Melanoma: Clinical Implications of Lost DormancyJournal of the American College of Surgeons, 2013
- Treatment Failure of a TLR-7 Agonist Occurs Due to Self-Regulation of Acute Inflammation and Can Be Overcome by IL-10 BlockadeThe Journal of Immunology, 2010
- Nature of Inflammatory Infiltrate in Superficial Cutaneous Malignancies During Topical Imiquimod TreatmentThe American Journal of Dermatopathology, 2007